In Shanghai’s ‘Science City,’ China’s Ascendant Biotechs Make Their Pitch to the World
Shanghai's 'Science City' biotechs pitch cheaper, faster drug trials against US rivals, citing a 11-month record.
CLAY TRIBUNE / THE ARCHIVE
Tag: pharma
AstraZeneca Invests $2 Billion in Summit Therapeutics as Four Deals Land Overnight
AstraZeneca invests $2 billion in Summit Therapeutics, Novo buys a Chinese obesity pill, and two biotech deals go the other way.
STAT’s Pharmalittle: GLP-1s Become Lifestyle Drugs, Merck and Daiichi Withdraw Lung Cancer Application
A weekly roundup of health headlines: GLP-1 drugs shift from medicine to lifestyle, Merck and Daiichi pull back on cancer, and more.
All 50 states sign on to Trump’s ‘favored nations’ drug pricing plan, expected to save Medicaid billions
Trump's 'favored nations' drug discount wins all 50 states; Medicaid saves $64B over 10 years. Pharma capitulates, TrumpRx launches.
IN8bio Hires LAVA Therapeutics’ Former CSO Oxana Polyakova as Senior VP of R&D
A newsletter tracking biotech hires posts but one name: Oxana Polyakova joins IN8bio, and the rest is silence.
Amgen (AMGN) Fell 5% on a Drug That Isn’t Even Its Own. Here’s the Lp(a) Bet Now in Question
A rival drug's failure sent Amgen's share price tumbling, casting doubt upon the very hypothesis its own late-stage asset relies upon.